Search Results for keywords:"glycine"

Found 2 results
Skip to main content

Search Results: keywords:"glycine"

  • Type:Notice
    Citation:90 FR 9320
    Reading Time:about 4 minutes

    The U.S. Department of Commerce has amended the final results of an administrative review involving Nagase & Co., Ltd. related to the antidumping duty on glycine from Japan for the period between October 31, 2018, and May 31, 2020. This amendment comes after a settlement agreement was reached between Nagase and the United States, which resolves a legal dispute that had previously been appealed up to the U.S. Court of Appeals for the Federal Circuit. As part of the settlement, Commerce will instruct U.S. Customs and Border Protection to liquidate entries of the glycine at certain rates determined by the agreement. The existing cash deposit rates will not be revised due to a superseding review determining different rates.

    Simple Explanation

    The U.S. and a company from Japan agreed to change some past rules about a special product called glycine, making sure the rules are fairer. They're deciding how much money the company should pay when bringing glycine into the U.S., but this won't change the current amount they have to pay for future shipments.

  • Type:Notice
    Citation:89 FR 101553
    Reading Time:about 7 minutes

    The U.S. Department of Commerce has concluded that certain producers or exporters from Japan sold glycine in the United States at prices below the normal value between June 1, 2022, and May 31, 2023. As a result, antidumping duties will be applied to the affected companies' products. The final decision was announced on December 16, 2024, and specific cash deposit rates and assessment rates have been established. Importers are reminded of their responsibility to report the reimbursement of these duties, or they may face additional charges.

    Simple Explanation

    The U.S. Department of Commerce found that some companies from Japan sold glycine, a type of chemical used in products like food and medicine, in the United States at unfairly low prices. Now, those companies have to pay extra money, called duties, to make things fair again, starting from June 2022 to May 2023.